Q-Finder: An Algorithm for Credible Subgroup Discovery in Clinical Data Analysis — An Application to the International Diabetes Management Practice Study
Publisher: Frontiers Artificial IntelligenceAuthors: C. Esnault, M-L. Gadonna, M. Queyrel, A. Templier, J-D. Zucker View publication Background Addressing the heterogeneity of both the outcome of a disease and the treatment response to an intervention is a mandatory pathway for regulatory approval of medicines. In randomized clinical trials (RCTs), confirmatory subgroup analyses focus on the assessment of drugs in […]
Rationale and methodology for a European pooled analysis of post-marketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: the REALI project
Publisher: BMJ openAuthors: N. Freemantle, R.C. Bonadonna, P. Gourdy, D. Mauricio, D. Mueller-Wieland, G. Bigot, A. Ciocca, C. Mauquoi, M. Rollot, M. Bonnemaire View publication Introduction Type 2 diabetes mellitus (T2DM) is a common and heterogeneous disease. Using advanced analytic approaches to explore real-world data may identify different disease characteristics, responses to treatment and progression patterns. Insulin glargine 300 units/mL (Gla-300) is a second-generation […]
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database
Publisher: DOM (Diabetes, Obesity and Metabolism)Authors: F.L. Zhou MD, H. Watada MD, Y; Tajima MS, M. Berthelot MS, D. Kang MS, C. Esnault MS, Y. Shuto MD, H. Maegawa MD, D. Koya MD View publication Aims To investigate the effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function preservation (RFP) using real-world data of patients with type 2 diabetes in […]
